Alzheimer’s disease (AD) is the most common form of dementia. There is no treatment to stop disease progression or slow it down. Thus patient care continues to be based on paramedical measures (speech therapy, welfare / social measures, and supportive care) and symptomatic treatments (cholinesterase inhibitors) or neuroprotectors (memantine) whose effectiveness is moderate.

MedDay SA au capital de 116 660 €
Siège social : 96 Boulevard Haussmann 75008 Paris
RCS PARIS 534 957 865
Publication Director : Dr Frédéric Sedel